SPRY Silverback Therapeutics Inc

Over the past year, insiders at ARS Pharmaceuticals have sold US$1.3 million worth of shares, notably Chief Business Officer Justin Chakma selling US$1.2 million, all of his holding, at a price below the current market value. This significant insider selling, without any corresponding purchases, raises questions about the insiders' confidence in the company's current valuation despite high insider ownership. Investors are advised to investigate further, considering this activity as a potential warning sign.

ARS Pharmaceuticals (NASDAQ:SPRY) saw its shares rise by 3.4% during Monday's trading, closing at $11.7690, though trading volume was significantly below average. Analysts currently hold a "Moderate Buy" consensus rating with a target price of $31.80, suggesting substantial potential upside. Despite missing EPS estimates but beating revenue in the last quarter, insiders still maintain a significant ownership stake in the company.

Next Century Growth Investors LLC has made a new investment in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), purchasing over 622,000 shares worth approximately $10.87 million in Q2 2025. While analysts maintain a "Moderate Buy" rating with a target price significantly above the current stock price, the company remains unprofitable and recently missed EPS estimates, despite revenue beating expectations. Insider selling by COO Brian Dorsey and Justin Chakma has also been noted.

ARS Pharmaceuticals (NASDAQ:SPRY) saw its share price increase by 8.1% on Wednesday, trading at $9.77 with a significantly lower volume than average. The company faces financial challenges, having missed Q3 EPS estimates despite beating revenue expectations, remaining unprofitable, and experiencing recent insider stock sales. Analyst ratings are mixed, resulting in a "Moderate Buy" consensus but with a wide range of price targets.

ARS Pharmaceuticals will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. Company executives Richard Lowenthal and Eric Karas will engage in a fireside chat on December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. The company's stock, SPRY, saw a 3.13% gain reflecting a positive market reaction on the news' publication day, adding approximately $28M to its valuation.

ARS Pharmaceuticals, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. CEO Richard Lowenthal and CCO Eric Karas will engage in a fireside chat on December 3 at 2:30 pm ET and hold one-on-one investor meetings. The company, known for its epinephrine nasal spray neffy®, aims to enhance visibility and discuss its strategic vision in the biopharmaceutical market.